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Abstract—Critically ill patients are often hyperglycemic 
and extremely diverse in their dynamics. Consequently, fixed 
protocols and sliding scales can result in error and poor 
control. A two-compartment glucose-insulin system model that 
accounts for time-varying insulin sensitivity and endogenous 
glucose removal, along with two different saturation kinetics is 
developed and verified in proof-of-concept clinical trials for 
adaptive control of hyperglycemia. The adaptive control 
algorithm monitors the physiological status of a critically ill 
patient, allowing real-time tight glycemic regulation. The 
bolus-based insulin administration approach is shown to result 
in safe, targeted stepwise glycemic reduction for three critically 
ill patients. 
 
Keywords—Adaptive control, critical care, glucose-insulin 
system model, hyperglycemia, insulin bolus 
 
 
I.  INTRODUCTION 
 
 Critically ill patients often experience stress-induced 
hyperglycemia and severe insulin resistance without history 
of diabetes (e.g. [1~7]). Hyperglycemia is not only a marker 
for severity of illness, it also worsens outcomes (e.g. [1, 5]). 
Van den Berghe et al. [5, 6] have shown that tight glucose 
control can reduce Intensive Care Unit (ICU) patient 
mortality by 45% if the glucose level is kept less than 6.1 
mmol/L for a cardiac care population. Krinsley [7] showed a 
6% total reduction in mortality over a broader ICU 
population with a higher glucose limit of 7.75 mmol/L. In 
addition, because automated glucose sensors are still in their 
infancy, initial implementations of automated glycemic 
control will likely be in a clinical environment. Automated 
control algorithms capable of tight regulation for glucose 
intolerant ICU patients would reduce mortality, as well as 
the current burden on ICU medical resources and time. 
 The proposed control algorithm needs to reduce 
elevated blood glucose levels in a controlled, predictable 
manner, while accounting for inter-patient variability and 
varying physiological condition. Hence, it must be adaptive 
and/or able to identify changes in patient dynamics, 
particularly with respect to insulin sensitivity. Previous 
works, such as Hovorka et al. [8], are primarily concerned 
with Type 1 diabetes and treatment of ambulatory 
individuals. The primary difference between this study and 
previous works that involve controlled insulin infusion 
experiments [8~10] is the focus on critical care patients, 
which can introduce significant additional dynamics due to 
illness, drug therapy and the impact of endogenous glucose 
removal. 
 
 
II.  MATHEMATICAL MODEL 
 
 Tight glucose control requires a patient-specific 
glucose-insulin system model that captures the fundamental 
dynamic responses to elevated glycemic levels and insulin. 
Doran et al. [10] used the minimal model by Bergman et al. 
[11], but failed to capture all transient dynamics, in 
particular the long term effect of exogenous insulin. Based 
on these results, an extended model was developed. 
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where G and I denote the glucose above an equilibrium level 
under constant feed, GE, and the plasma insulin from an 
exogenous insulin input respectively. Insulin utilization over 
time is represented by Q, with k accounting for the effective 
insulin half-life in the system, which is set to 70 min as a 
median of a range of reported values [12, 13]. It can be 
adapted during a trial to better represent observed patient 
dynamics. Patient endogenous glucose removal and insulin 
sensitivity are pG and SI respectively. The parameter V is the 
insulin distribution volume and n is the first order decay rate 
for plasma insulin. External nutrition and insulin input are 
P(t) and uex(t) respectively. Michaelis-Menten parameters   I 
and   G respectively define the plasma insulin disappearance 
saturation and the insulin-stimulated glucose removal 
saturation. 
 Many studies have investigated insulin saturation in 
vivo (e.g. [12~14]). Two saturation mechanisms are 
included in (1) and (3), one for insulin action, the other for 
insulin transport from plasma to interstitial sites. The 
parameter,   I, in (3) bounds the plasma insulin 
disappearance rate. First order plasma insulin disappearance 
rate at low insulin concentration, n, is set to 0.16 min-1, a 
value that is fairly consistent across many studies (e.g. [14, 
15]). The value of   I is set to 0.0017 L/mU, which is also 
consistent across many studies (e.g. [14, 15]). 
 Saturation in insulin-stimulated glucose removal has 
been evidenced in several clinical investigations (e.g. [15, 
16]). The parameter,   G, in (1) defines the insulin-stimulated 
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glucose removal saturation. This study uses   G=1/65 L/mU 
as an initial conservative choice from previous reported 
results (e.g. [15, 16]), to ensure that saturation is more likely 
to be underestimated. 
 The model does not include the endogenous insulin 
production rate because it can be highly variable and 
difficult to obtain quickly in critical care, even though it is 
fairly consistent across the non-critically ill population (e.g. 
[8, 11, 15]). Therefore, the effect of endogenous insulin is 
combined with the effect of glucose to enhance glucose 
removal and inhibit endogenous glucose production for 
these short trials. The result is a time-varying parameter, pG 
that represents the body’s ability to regulate blood glucose 
without exogenous insulin, or more simply, metabolic 
glucose resistance. The added saturation mechanism on 
insulin effect in (1) to (3) creates a unique index of insulin 
sensitivity, SI in contrast to other model-based measures 
(e.g. [16, 17]). This approach allows SI to more closely 
approximate the true tissue sensitivity to insulin. 
 
 
III.  PARAMETER FITTING AND CONTROL METHOD 
 
 Using generic values for   G,   I, n, k and V limits the 
only unknowns in the model to pG and SI. This study utilizes 
an integration-based method developed by Hann and 
Hickman [18] to achieve high accuracy real-time tracking in 
pG and SI. Both pG and SI are defined as first order piecewise 
linear to reduce computational intensity while capturing 
slow variations. The method results in a simple convex least 
squares problem that demands little computational time and 
intensity, in contrast to the commonly used non-linear 
recursive least squares routine that is non-convex and 
starting point dependent [19]. In addition, this approach is 
insensitive to measurement noise, a problem with gradient-
based [10], as it effectively low-pass filters the data in the 
numerical integration summations. Constraints are placed on 
both parameters to ensure they are within the 
physiologically valid range (e.g. [8, 12, 13, 16, 17, 20~22]). 
 Prior to making an injection to achieve a corresponding 
blood glucose target, pG and SI are fitted using prior data. 
The interval between injections is one hour in this research. 
Prediction for the glucose profile one hour onwards is made 
by assuming the final values of pG and SI remain constant 
during following hour. The required bolus size to achieve 
the target blood glucose level is then determined using a 
bisection method and (1)-(3). 
 Insulin sensitivity can trade off with insulin effective 
half-life and its effective saturation limit. When the effective 
insulin half-life differs by greater than 50% from the 
originally assumed value of 70 min, the impact is transferred 
into the value of SI and results in non-physiological saw 
tooth profiles. 
 Adapting the insulin half-life, or k, restores more 
constant and physiologically valid variations in SI. The 
glucose removal saturation parameter,   G, is kept constant. 
Adapting the saturation level in real-time is difficult because 
its detection is available only when significant saturation 
occurs, followed by large target error. For patient safety,   G 
is set to 1/65 L/mU, corresponding to the highest reported 
saturation level found [13] to avoid the risk of administering 
excess insulin, due to seeing the patient as being at the 
saturation limit. 
 For effective control, ineffective delayed insulin, which 
is unused due to saturation, is always maintained below 30 
mU/L because of the extremely limited effect of any further 
insulin input. This limitation, in turn, limits the achievable 
glucose reduction. When the desired reduction reaches 
beyond this boundary, the target is reset to an achievable 
value, preventing unnecessary insulin being given to the 
patients and adding another level of safety. 
 
 
IV.  CLINICAL TRIAL METHODOLOGY 
 
 The proof-of-concept clinical trials consist of an insulin 
challenge hour followed by four hours of tight glycemic 
control. Each blood glucose target to be achieved one hour 
onwards is set at the end of that hour, targeting a 10 to 20% 
hourly reduction. The minimum target level is 4.5 mmol/L. 
Ethical consent was obtained from the Canterbury Ethics 
Committee. 
 The trial begins at 0700 hours, at which time any insulin 
infusion is held constant with known constant naso-gastric 
feed maintained throughout the trial. Blood glucose is 
monitored hourly until 1000 hours to determine the patients’ 
equilibrium blood glucose level, GE. At 1000 hours, patients 
are injected with a fixed 1500 mU ActrapidTM insulin bolus 
via an intravenous cannula using a Graseby 3500 syringe 
pump. Plasma glucose is measured at 15-minute intervals 
until 1100 hours. Paired blood samples are taken and 
analyzed using a bedside GlucocardTM Test Strip II glucose 
testing kit, which has 7% error [23]. 
 Patient specific parameters, pG and SI, are fitted using 
the first hour of data. Based on these values, an insulin bolus 
size is calculated by the controller to achieve the targeted 
glycemic reduction. Blood glucose is monitored every 30 
minutes, and patient specific parameters are refit every hour 
using the data obtained in the previous hour. Following each 
refit, the controller determines the insulin bolus required to 
achieve the targeted glycemic reduction. Hence, the overall 
approach is a bolus driven, adaptive control method that 
uses prior data to update the patient specific parameters 
 
 
V.  RESULTS AND DISCUSSION 
 
A.  Trial A 
 
 Patient A was a 76 year old male post coronary artery 
bypass surgical patient admitted into the ICU 33 days before 
the trial. The results are presented in Fig. 1. The patient was 
diagnosed with respiratory failure secondary to mediastinal 
sepsis and heart failure. The trial started with GE=8.3 
mmol/L and the targeted hourly reduction was 10%. This 
first trial used   G=1/25 L/mU, effectively seeing the patient 
as having a lower glucose clearance saturation limit. 
 Insulin sensitivity, SI, took on a saw tooth shape 
throughout this trial as a result of compensating for an 
incorrect insulin half-life parameter, k. The protocol for 
modifying k was introduced after this trial. When the half-
life was corrected, the fitted SI became smoother and more 
physiologically valid. At 240 min, the controller demanded 
a larger bolus than the two previous injections (4.45 vs. 1.95 
and 2.45 U) to achieve a similar percentage reduction 
because the model saw the patient as being at the saturation 
limit, thus requiring much more insulin to achieve the 
desired level. Although the patient did not suffer a 
hypoglycemic episode, the saturation limit was raised, with 
 
G lowered to 1/65 L/mU for patient safety.  
 
B.  Trial B 
 
 Patient B was a 77-year-old female admitted to the ICU 
30 days before the trial, diagnosed with diarrhea and sepsis 
due to lung injury. The trial began with GE=11.65 mmol/L, 
and the targeted hourly reduction was 15%. The results are 
presented in Fig. 2. 
 This trial demonstrated the impact of real-time 
modification of the insulin effective half-life, k. The data 
collected from the first two hours resulted in a saw tooth 
shape for SI similar to Trial A. The effective insulin half-life 
was automatically modified to 35 minutes at 120 min to 
eliminate the non-physiological variation of SI from a 
grossly incorrect assumed half-life. The immediate impact 
of this alteration is a much smoother and more 
physiologically realistic SI variation from 120 min onwards, 
together with much lower resulting target errors. 
 The target reduction for 240 and 300 min were set lower 
than 15% because the controller predicted that glucose 
clearance saturation would limit the achievable drop. 
However, this patient probably had a higher saturation limit 
than assumed, or   G higher than 1/65 L/mU. Hence, these 
two target errors are larger. An extended trial would have 
allowed the identification of a more correct value. 
 
C.  Trial C 
 
 Patient C was a 62-year-old male Type 2 diabetic 
admitted to the ICU 6 days before the trial with an acute 
abdominal aortic aneurysm. The trial started with GE=10.3 
mmol/L, and the targeted hourly reduction was 15%. The 
results are shown in Fig. 3. 
 This patient’s modeled pG and SI are both very smooth 
with minor discontinuity between each fit. This result 
indicates that the generic parameters used were similar to 
the actual patient values. The first two target glucose errors 
are larger because of the rapid decline in SI from 0 to 120 
min due to the onset of the trial or the controller adapting 
from initial values. During this time, the patient’s 
metabolism might have undergone alterations caused by the 
introduction of significant exogenous insulin, or the patient 
was becoming more agitated, triggering increased stress 
hormone secretion, and therefore reducing insulin 
sensitivity. The last two predictions had minimal error, 
showing that the controller had ‘dialed in’ and adapted to 
match the patient’s dynamics. 
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 VI. CONCLUSIONS 
 
 The clinical trials conducted during this study 
demonstrate the potential of the control algorithm designed 
for set-point regulation of hyperglycemia across a range of 
critically ill patients. The model and algorithm developed 
are capable of capturing a patient’s glucose-insulin system 
dynamics, despite inter-patient variability and time varying 
physiological condition. The physiologically justified, non-
linear mathematical model developed accounts for non-
linear saturation of plasma insulin disappearance rate and its 
saturable utilization to reduce blood glucose levels. Further 
investigation into glucose clearance saturation limit and 
methods of real-time adaptation should permit the controller 
to obtain better performance. The addition of delayed insulin 
utilization via a convolution integral has accounted for the 
accumulation dynamic seen in prior clinical trials [10]. 
Removing endogenous insulin production from the model 
reduced model complexity and resulted in a unique 
metabolic glucose resistance index, pG. Finally, an 
integration-based method is used for identifying patient 
specific time-varying parameters in real-time, resulting in a 
convex, computationally simple, linear, least squares 
solution. Overall, the research presented is a significant step 
towards more fully automated adaptive control of 
hyperglycemia in critically ill patients. 
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